Sanofi | SNY - Operating Expenses




Sanofi reported EUR10.52B in Operating Expenses for its fiscal quarter ending in September of 2024.

Operating Expenses Change Date
AbbVie USD 16.59B 6.05B Dec/2024
Amgen USD 7.53B 3B Sep/2024
AstraZeneca USD 10.8B 760M Sep/2024
Bristol-Myers Squibb USD 17.14B 6.63B Sep/2024
Canopy Growth CAD 108.61M 21.09M Sep/2024
Corcept Therapeutics USD 135.95M 7.74M Sep/2024
Drreddys Laboratories INR 62.61B 3.81B Sep/2024
Eli Lilly USD 7B 6M Sep/2024
Galapagos EUR 114.15M 1.9M Sep/2024
Genmab DKK 3.44B 148M Sep/2024
GlaxoSmithKline GBP 7.82B 2.15B Sep/2024
Glaxosmithkline GBP 7.35B 1.11B Sep/2024
Indivior 431M 212M Jun/2024
J&J USD 18.63B 500M Dec/2024
Merck USD 12.7B 2.97B Sep/2024
Novartis USD 11.28B 1.73B Dec/2024
Novartis USD 8.73B 115M Sep/2024
Pacira USD 144.86M 2.19M Sep/2024
Perrigo USD 1.01B 8.3M Sep/2024
Pfizer USD 12.42B 2.11B Sep/2024
Prestige Brands USD 73.04M 122.06M Sep/2024
Roche Holding CHF 9.95B 13.54B Jun/2024
Sanofi EUR 10.07B 969M Sep/2024
Sanofi EUR 10.52B 1.42B Sep/2024
Supernus Pharmaceuticals USD 1.01B 857.04M Sep/2024
UCB EUR 1.23B 1.31B Jun/2024
Zoetis USD 5.23B 3.78B Sep/2024